サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1605886

芽球性形質細胞様樹状細胞腫瘍市場、規模、シェア、動向、産業分析レポート：治療別、エンドユーザー別、地域別 - 市場予測 2025年～2034年

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Size, Share, Trends, Industry Analysis Report: By Treatment, End Users, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 118 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
芽球性形質細胞様樹状細胞腫瘍市場、規模、シェア、動向、産業分析レポート：治療別、エンドユーザー別、地域別 - 市場予測 2025年～2034年
出版日: 2024年11月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、芽球性形質細胞様樹状細胞腫瘍（BPDCN）の市場規模は2034年までに2,828億1,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

芽球性形質細胞様樹状細胞腫瘍（BPDCN）市場は、この疾患に対する認識の高まりと治療オプションの進歩によって大きな成長を遂げています。主な促進要因としては、BPDCNの罹患率の上昇、新規薬剤や免疫療法などの標的療法や革新的な治療法の開発などが挙げられ、これらは治療の展望を広げています。

市場の機会は、患者の転帰を改善することを目的とした進行中の調査や臨床試験、個別化医療アプローチの導入によって支えられています。早期診断の重視の高まりや次世代シーケンサー技術の統合といった動向も、市場を形成すると予想されます。全体として、BPDCN市場は、治療選択肢の改善と患者ケアの向上に焦点を当てたこれらの要因により、大きく成長すると予想されます。

芽球性形質細胞様樹状細胞腫瘍市場レポート・ハイライト

治療分析別では、免疫療法がBPDCN市場で最も急成長しています。これは、標的治療薬やチェックポイント阻害薬の進歩により、BPDCN治療において有望な結果が得られているためです。免疫療法は、その有効性と副作用の軽減により、従来の化学療法よりもますます好まれるようになってきています。

エンドユーザー別の分析では、高度なインフラと包括的な治療能力により、病院セグメントがBPDCN治療市場を独占しています。専門クリニックも、より集中的な治療への動向を反映し、専門的な治療と患者管理を提供することで成長をみせています。

北米は依然としてBPDCNの最大市場であり、高度なヘルスケアインフラと高い研究活動に支えられています。しかし、アジア太平洋地域は、ヘルスケアへの投資の増加とBPDCNに対する認識の高まりにより、最も急速に成長している地域です。

BPDCN市場に積極的に参入している主な企業には、Stemline Therapeutics社（現在はMenarini Group傘下）、Celgene Corporation社（Bristol-Myers Squibb社が買収）、Pfizer Inc.社、Johnson &Johnson社、Novartis AG社、Takeda Pharmaceutical社、Amgen Inc.社、Gilead Sciences社、F. Hoffmann-La Roche Ltd.社、Merck &Co., Inc.社、AbbVie Inc.社、AstraZeneca社、Sanofi社、Bayer AG社、Incyte Corporation社などがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の芽球性形質細胞様樹状細胞腫瘍市場の洞察

  • 市場スナップショット
  • 芽球性形質細胞様樹状細胞腫瘍市場力学
    • 促進要因と機会
      • 標的療法の採用増加
      • 診断技術の進歩
    • 抑制要因と課題
      • 治療費が高い
  • PESTEL分析
  • 芽球性形質細胞様樹状細胞腫瘍市場のエンドユーザーの動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の芽球性形質細胞様樹状細胞腫瘍市場：治療別

  • 主な調査結果
  • イントロダクション
  • 化学療法
  • 免疫療法
  • 幹細胞移植

第6章 世界の芽球性形質細胞様樹状細胞腫瘍市場：エンドユーザー別

  • 主な調査結果
  • イントロダクション
  • 病院
  • 専門クリニック
  • その他

第7章 世界の芽球性形質細胞様樹状細胞腫瘍市場：地域別

  • 主な調査結果
  • イントロダクション
    • 芽球性形質細胞様樹状細胞腫瘍市場評価：地域別、2020～2034年
  • 北米
    • 北米：治療別、2020～2034年
    • 北米：エンドユーザー別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：治療別、2020～2034年
    • 欧州：エンドユーザー別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：治療別、2020～2034年
    • アジア太平洋地域：エンドユーザー別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：治療別、2020～2034年
    • 中東・アフリカ：エンドユーザー別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：治療別、2020～2034年
    • ラテンアメリカ：エンドユーザー別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Stemline Therapeutics（Menarini Group）
  • ImmunoGen, Inc.
  • Mustang Bio
  • Genentech, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Cellex Patient Treatment GmbH
  • Xencor
  • Resverlogix
  • Celgene Corporation（Bristol-Myers Squibb）
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
図表

List of Tables:

  • Table 1 Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 2 Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 3 North America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 4 North America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 5 US: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 6 US: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 7 Canada: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 8 Canada: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 9 Europe: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 10 Europe: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 11 UK: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 12 UK: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 13 France: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 14 France: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 15 Germany: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 16 Germany: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 17 Italy: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 18 Italy: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 19 Spain: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 20 Spain: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 21 Netherlands: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 22 Netherlands: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 23 Russia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 24 Russia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 25 Rest of Europe: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 26 Rest of Europe: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 27 Asia Pacific: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 28 Asia Pacific: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 29 China: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 30 China: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 31 India: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 32 India: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 33 Malaysia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 34 Malaysia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 35 Japan: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 36 Japan: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 37 Indonesia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 38 Indonesia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 39 South Korea: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 40 South Korea: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 41 Australia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 42 Australia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 43 Rest of Asia Pacific: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 44 Rest of Asia Pacific: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 45 Middle East & Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 46 Middle East & Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 47 Saudi Arabia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 48 Saudi Arabia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 49 UAE: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 50 UAE: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 51 Israel: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 52 Israel: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 53 South Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 54 South Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 55 Rest of Middle East & Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 56 Rest of Middle East & Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 57 Latin America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 58 Latin America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 59 Mexico: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 60 Mexico: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 61 Brazil: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 62 Brazil: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 63 Argentina: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 64 Argentina: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • Table 65 Rest of Latin America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • Table 66 Rest of Latin America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • List of Figures:
  • Figure 1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, 2020-2034 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2024 & 2034 (USD Million)
  • Figure 8. Market by End Use
  • Figure 9. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2024 & 2034 (USD Million)
目次
Product Code: PM5233

The blastic plasmacytoid dendritic cell neoplasm market size is expected to reach USD 282.81 billion by 2034, according to a new study by Polaris Market Research. The report "Blastic Plasmacytoid Dendritic Cell Neoplasm Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Immunotherapy, and Stem Cell Transplantation), End Users, Region (North America, Europe, Asia Pacific, Latin America and the Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The blastic plasmacytoid dendritic cell neoplasm market is experiencing significant growth driven by increasing awareness of the disease and advancements in treatment options. Key drivers include the rising incidence of BPDCN and the development of targeted therapies and innovative treatments, such as novel drugs and immunotherapies, which are expanding the treatment landscape.

Opportunities in the market are supported by ongoing research and clinical trials aimed at improving patient outcomes and the introduction of personalized medicine approaches. Trends such as the growing emphasis on early diagnosis and the integration of next-generation sequencing techniques are also expected to shape the market. Overall, the BPDCN market is expected to grow substantially due to these factors, with a focus on improving therapeutic options and enhancing patient care.

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Report Highlights

By treatment analysis, immunotherapy is the most rapidly growing segment in the BPDCN market. This is due to its promising outcomes in BPDCN treatment, driven by advancements in targeted therapies and checkpoint inhibitors. Immunotherapy is being increasingly preferred over traditional chemotherapy due to its efficacy and reduced side effects.

By end users analysis, the hospital segment dominates the market for BPDCN treatments, owing to their advanced infrastructure and comprehensive care capabilities. Specialty clinics are also seeing growth as they offer specialized treatments and patient management, reflecting a trend toward more focused care.

North America remains the largest market for BPDCN, supported by advanced healthcare infrastructure and high research activity. However, Asia Pacific is the fastest-growing region, driven by increasing investments in healthcare and rising awareness of BPDCN.

Major players actively participating in the BPDCN market include Stemline Therapeutics (now part of Menarini Group); Celgene Corporation (acquired by Bristol-Myers Squibb); Pfizer Inc., Johnson & Johnson; Novartis AG; Takeda Pharmaceutical Company Limited; Amgen Inc.; Gilead Sciences; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; AbbVie Inc.; AstraZeneca; Sanofi; Bayer AG; and Incyte Corporation.

Polaris market research has segmented the blastic plasmacytoid dendritic cell neoplasm market report based on treatment, end users, and region:

By Treatment Outlook (Revenue - USD Billion, 2020-2034)

  • Chemotherapy
  • Immunotherapy
  • Stem Cell Transplantation

By End Users Outlook (Revenue - USD Billion, 2020-2034)

  • Hospitals
  • Specialty Clinics
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of the Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market Insights

  • 4.1. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Market Snapshot
  • 4.2. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Adoption of Targeted Therapies
      • 4.2.1.2. Advancements in Diagnostic Techniques
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High treatment cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market End Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
  • 5.3. Chemotherapy
    • 5.3.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Chemotherapy, by Region, 2020-2034 (USD Million)
  • 5.4. Immunotherapy
    • 5.4.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Immunotherapy, by Region, 2020-2034 (USD Million)
  • 5.5. Stem Cell Transplantation
    • 5.5.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Stem Cell Transplantation, by Region, 2020-2034 (USD Million)

6. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Hospitals, by Region, 2020-2034 (USD Million)
  • 6.4. Specialty Clinics
    • 6.4.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Specialty Clinics, by Region, 2020-2034 (USD Million)
  • 6.5. Others
    • 6.5.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Assessment, By Geography, 2020-2034 (USD Million)
  • 7.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - North America
    • 7.3.1. North America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
    • 7.3.2. North America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.3.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - US
      • 7.3.3.1. US: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.3.3.2. US: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.3.4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Canada
      • 7.3.4.1. Canada: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.3.4.2. Canada: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • 7.4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Europe
    • 7.4.1. Europe: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
    • 7.4.2. Europe: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.4.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - UK
      • 7.4.3.1. UK: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.4.3.2. UK: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.4.4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - France
      • 7.4.4.1. France: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.4.4.2. France: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.4.5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Germany
      • 7.4.5.1. Germany: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.4.5.2. Germany: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.4.6. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Italy
      • 7.4.6.1. Italy: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.4.6.2. Italy: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.4.7. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Spain
      • 7.4.7.1. Spain: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.4.7.2. Spain: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.4.8. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Netherlands
      • 7.4.8.1. Netherlands: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.4.8.2. Netherlands: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.4.9. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Russia
      • 7.4.9.1. Russia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.4.9.2. Russia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.4.10. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.4.10.2. Rest of Europe: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • 7.5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Asia Pacific
    • 7.5.1. Asia Pacific: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
    • 7.5.2. Asia Pacific: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.5.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - China
      • 7.5.3.1. China: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.5.3.2. China: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.5.4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - India
      • 7.5.4.1. India: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.5.4.2. India: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.5.5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Malaysia
      • 7.5.5.1. Malaysia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.5.5.2. Malaysia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.5.6. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Japan
      • 7.5.6.1. Japan: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.5.6.2. Japan: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.5.7. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Indonesia
      • 7.5.7.1. Indonesia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.5.7.2. Indonesia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.5.8. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - South Korea
      • 7.5.8.1. South Korea: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.5.8.2. South Korea: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.5.9. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Australia
      • 7.5.9.1. Australia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.5.9.2. Australia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.5.10. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.5.10.2. Rest of Asia Pacific: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • 7.6. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
    • 7.6.2. Middle East & Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.6.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.6.3.2. Saudi Arabia: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.6.4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - UAE
      • 7.6.4.1. UAE: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.6.4.2. UAE: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.6.5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Israel
      • 7.6.5.1. Israel: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.6.5.2. Israel: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.6.6. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - South Africa
      • 7.6.6.1. South Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.6.6.2. South Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.6.7. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.6.7.2. Rest of Middle East & Africa: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
  • 7.7. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Latin America
    • 7.7.1. Latin America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
    • 7.7.2. Latin America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.7.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Mexico
      • 7.7.3.1. Mexico: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.7.3.2. Mexico: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.7.4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Brazil
      • 7.7.4.1. Brazil: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.7.4.2. Brazil: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.7.5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Argentina
      • 7.7.5.1. Argentina: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.7.5.2. Argentina: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)
    • 7.7.6. Blastic Plasmacytoid Dendritic Cell Neoplasm Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by Treatment, 2020-2034 (USD Million)
      • 7.7.6.2. Rest of Latin America: Blastic Plasmacytoid Dendritic Cell Neoplasm Market, by End Use, 2020-2034 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Stemline Therapeutics (Menarini Group)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. ImmunoGen, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Mustang Bio
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Genentech, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Jazz Pharmaceuticals, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Cellex Patient Treatment GmbH
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Xencor
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Resverlogix
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Celgene Corporation (Bristol-Myers Squibb)
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Pfizer Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Johnson & Johnson
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Novartis AG
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development